Thrasos is a private, clinical-stage, bio-therapeutics company focused on the discovery and development of therapies to prevent and treat kidney disease. The Company has begun clinical testing of its first drug candidate, THR-184, for Acute Kidney Injury and is developing a second compound, THR-123, for use in Chronic Kidney Disease. The Company's drug candidates are proprietary peptides designed to selectively activate the key receptors of the bone morphogenetic protein family.